Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of exposure therapy for panic disorder with agoraphobia
NL-OMON34949Phase 3Withdrawn
- Sponsor
- Utrecht University
- Start
- Feb 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of d-cycloserine in Agoraphobia with panic disorder (PD/A) (3 arms), sponsored by Utrecht University. Primary endpoints: Panic Disorder Severity Scale and Subjective Units of Distress Scale. Planned start Feb 2010; status: withdrawn.
02
Drugs
d-cycloserine
03
Conditions
Agoraphobia with panic disorder (PD/A)
Beyond the preview
Go deeper on NL-OMON34949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34949.